AU1969201A - Retro-anandamides, high affinity and stability cannabinoid receptor ligands - Google Patents

Description

WO 01/28498 PCT/USOO/41248 RETRO-ANANDAMIDES, HIGH AFFINITY AND STABILITY CANNABINOID RECEPTOR LIGANDS Field of the Invention 5 The present invention relates generally to cannabinoid analogs and is more particularly concerned with new and improved retro-anandamide cannabinoid analogs exhibiting high binding affinities for cannabinoid receptors, pharmaceutical preparations employing these analogs and methods of administering therapeutically effective amounts of the preparations to provide a 10 physiological effect. Background of the Invention Classical cannabinoids such as the marijuana derived cannabinoid

A

9 -tetrahydrocannabinol, (A 9 -THC) produce their pharmacological effects through 15 interaction with specific cannabinoid receptors in the body. So far, two cannabinoid receptors have been characterized: CB1, a central receptor found in the mammalian brain and peripheral tissues and CB2, a peripheral receptor found only in the peripheral tissues. Compounds that are agonists or antagonists for one or both of these receptors have been shown to provide a variety of 20 pharmacological effects. See, for example, Pertwee, R.G., Pharmacoloqy of cannabinoid CB1 and CB2 receptors, Pharmacol. Ther., (1997) 74:129 - 180 and Di Marzo, V., Melck, D., Bisogno, T., DePetrocellis, L., Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action, Trends Neurosci. (1998) 21:521 - 528. 25 In addition to acting at the cannabinoid receptors, cannabinoids such as

-A

9 -THC also affect cellular membranes, thereby producing undesirable side effects such as drowsiness, impairment of monoamine oxidase function and impairment of non-receptor mediated brain function. The addictive and psychotropic properties of some cannabinoids also limit their therapeutic value. 30 Arachidonylethanolamide (anandamide) is an endogenous lipid that binds to and activates the CB1 cannabinoid receptor with approximately WO 01/28498 PCT/USOO/41248 equal affinity to that of A-THC. 0 11 H ---. y -C -I- OH 5 <Anandamide Anandamide also exhibits biochemical and pharmacological properties similar to that of A-THC, albeit with a longer onset time and shorter duration of action. 10 The exact physiological role of anandamide, a cannabinoid agonist, is still not clearly understood. It is known that an enzyme called "anandamide amidase" hydrolyzes anandamide. It is presumed that the magnitude of action and relatively short duration of action of anandamide is due to a rapid inactivation process consisting of carrier-mediated transport into cells followed by intra 15 cellular hydrolysis by anandamide amidase. Presently known anandamide analogues show susceptibility towards enzymatic hydrolysis and/or have low receptor affinity. There is considerable interest in developing analogs of anandamide possessing high CB1 receptor affinity and/or metabolic stability. Such analogs may offer a rational therapeutic 20 approach to a variety of disease states in which elevation of anandamide analog levels may bring about a more favorable response with fewer side effects and greater metabolic stability than direct activation of CB1 receptors by anandamide. 25 Summary of the Invention It has now been found that certain novel analogs of anandamide and physiologically acceptable salts thereof possess improved CB1 receptor affinity and selectivity and/or greater metabolic stability than anandamide. The term "metabolic stability" as used herein refers to the resistance to hydrolysis of the 30 subject anandamide analog by anandamide amidase. Thus, the novel analogues described herein should have a longer duration of action then anandamide. 2 WO 01/28498 PCT/USOO/41248 Thus one aspect of the invention are the analogs of anandamide generally shown in structural formula 1. The novel analogs were prepared by structural modification of anandamide. The modifications were primarily made in the ethanolamido head group and included reversing the positions of the NH and CO 5 groups. Such anandamide analogues wherein the NH and CO group positions are reversed are known as "retro-anandamides". R2 Y R- -133 10 structural R1 formula 1 wherein: X is selected from the group consisting of C=0, and C=S; 15 Yis NH; R, is selected from the group consisting of n-C 5 H,,Z, n-C6 12 Z, n-C 7 H,,Z, and 11 '-C(CH 3

)

2

(CH

2

)

5

CH

2 Z, wherein Z is selected from the group consisting of H, halogen, N3, NCS, OH, CN and -CH = CH-1;

R

2 is selected from the group consisting of H, CH 3 , and (CH 3

)

2 ; and 20 R. is selected from the group consisting of CH 3 , CHX 2 , CH 2 X, CH = CH 2 ,

CH

2 0CH 3 , -C=CH, -O(CH 2 )nCH 3 , -S(CH 2 )nCH., -N--(CH 2 )nCH

(CH

2 )mCH 3 wherein n and m are each a number from 0 to about 7, 25 wherein X is selected from the group consisting of -x Y N and CH and Y and Z are each selected from the z group consisting of (CH 2 )n, 0, N, and S, and wherein n is a number from 0 to about 7, 30 3 WO 01/28498 PCT/USOO/41248 X- wherein X, Y and Z are each selected from the group consisting of CH and N, wherein R4, R5 and R6 are each selected from he 5 ,R6 group consisting of halogen, N 3 , NCS, OCH 3 , CH 3 , R4

CH

2

CH

3 , NO 2 , NH 2 and phenyl. In another aspect of the invention, increased metabolic stability and 10 resistance to enzymatic hydrolysis are achieved by introducing steric bulk in the form of alkyl groups around the amide bond or suitable modification of the amide bond itself. The inventive anandamide analogues of this invention are metabolically stable (i.e., have low or no enzyme turnover) and show significantly higher 15 cannabinoid receptor affinities and selectivities. The improved receptor affinity and selectivity and/or metabolic stability create therapeutic uses for the novel analogs. Therefore, the novel compounds described herein, and physiologically acceptable salts thereof, represent potentially useful materials for providing a physiological effect to treat The inventive analogs described herein, and 20 physiologically acceptable salts thereof, have high potential when administered in therapeutically effective amounts for providing a physiological effect useful to treat pain; peripheral pain; glaucoma; epilepsy; nausea such as associated with cancer chemotherapy; AIDS Wasting Syndrome; cancer; neurodegenerative diseases including Multiple Sclerosis, Parkinson's Disease, Huntington's Chorea 25 and Alzheimer's Disease; to enhance apetite; to reduce fertility; to prevent or reduce diseases associated with motor function such as Tourette's syndrome; to provide neuroprotection; to produce peripheral vasodilation and to suppress memory. Thus, another aspect of the invention is the administration of a therapeutically effective amount of an inventive compound, or a physiologically 30 acceptable salt thereof, to an individual or animal to provide a physiological effect. 4 WO 01/28498 PCT/USOO/41248 Description of Some Preferred Embodiments As used herein a "therapeutically effective amount" of a compound, is the quantity of a compound which, when administered to an individual or animal, results in a sufficiently high level of that compound in the individual or animal to 5 cause a discernible increase or decrease in stimulation of cannabinoid receptors. Physiological effects which result from cannabinoid receptor stimulation include analgesia, decreased nausea resulting from chemotherapy, sedation and increased appetite. Other physiological functions include relieving intraocular pressure in glaucoma patients and suppression of the immune system. Typically, 10 a "therapeutically effective amount" of the compound ranges from about 10 mg/day to about 1,000 mg/day. As used herein, an "individual" refers to a human. An "animal" refers to, for example, veterinary animals, such as dogs, cats, horses and the like, and farm animals, such as cows, pigs and the like. 15 The compound of the present invention can be administered by a variety of known methods, including orally, rectally, or by parenteral routes (e.g., intramuscular, intravenous, subcutaneous, nasal or topical). The form in which the compounds are administered will be determined by the route of administration. Such forms include, but are not limited to, capsular and tablet 20 formulations (for oral and rectal administration), liquid formulations (for oral, intravenous, intramuscular or subcutaneous administration) and slow releasing microcarriers (for rectal, intramuscular or intravenous administration). The formulations can also contain a physiologically acceptable vehicle and optional adjuvants, flavorings, colorants and preservatives. Suitable physiologically to 25 acceptable vehicles may include, for example, saline, sterile water, Ringer's solution, and isotonic sodium chloride solutions. The specific dosage level of active ingredient will depend upon a number of factors, including, for example, biological activity of the particular preparation, age, body weight, sex and general health of the individual being treated. 30 The inventive retro-anandamides can generally be described with reference to structural formula 1 includes physiologically acceptable salts thereof. 5 WO 01/28498 PCT/USOO/41248 R2 y -'

'-R

3 structural formula 1 wherein: X is selected from the group consisting of C=0, and C=S; Y is NH; R, is selected from the group consisting of n-C 5

H

1 0 Z, n-C612Z, n-C 7

H

14 Z, and 1'1 '-C(CH 3

)

2

(CH

2

),CH

2 Z, wherein Z is selected from the group consisting of H, halogen, N3, NCS, OH, CN and -CH = CH-l;

R

2 is selected from the group consisting of H, CH 3 , and (CH 3

)

2 ; and

R

3 is selected from the group consisting of CH 3 , CHX 2 , CH 2 X, CH = CH 2 ,

CH

2 0CH 3 , -C=-CH, -O(CH 2 )nCH 3 , -S(CH 2 )nCH 3 , -N-(CH )nCH

(CH

2 )mCH 3 wherein n and m are each a number from 0 to about 7, D wherein X is selected from the group consisting of -x y N and CH and Y and Z are each selected from the z group consisting of (CH 2 )n, 0, N, and S, and wherein n is a number from 0 to about 7, 5 wherein X, Y and Z are each selected from the / group consisting of CH and N, 0 6 WO 01/28498 PCT/US00/41248 _ R6 wherein R4, R5 and R6 are each selected from he RR group consisting of halogen,

N

3 , NCS,

OCH

3 , CH 3 , R4 CH 2

CH

3 , NO 2 , NH 2 and phenyl. 5 The novel retro-anandamide analogs possess high metabolic stability and/or high CB1 receptor affinity and selectivity. The high CB1 receptor affinity and selectivity functions to make these analogs useful for the treatment of at least the previously described conditions when administered to an individual or animal in a therapeutically effective amount without the unwanted side effects 10 that are a result of use of known cannabinoids to stimulate the CB1 and CB2 receptors. Additionally, the high metabolic stability of the novel analogs function to provide a longer lasting effect than is typical of known cannabinoids. The inventive materials were generally prepared according to scheme 1 below: OH a

N

3 b 0

NH

2 C N R - - H 15 (a) ZnN 6 Py, PhP, DIAP, toluene; (b) LiAlH 4 , diethyl ether; (c) Et 3 N, DMF, acid chloride. General. Column chromatography was carried out using Selecto Scientific active silica gel (230 - 400 mesh), and eluents were distilled before use. 20 Solvents for reactions were dried or purified as required. Reactions were carried out under argon atmospheres unless otherwise noted. Arachidonyl alcohol was purchased from Nu-Chek-Prep, Inc., Elysian, Mn. Rat brains were purchased from Pelfreeze Rogers, Ar. 25 Arachidonyl azide. To a magnetically stirred solution of 3.6 g (13.7 mmol) of Ph 3 P in 30 mL anhydrous toluene was added 2.0 g (6.9 mmol) of arachidonyl alcohol. Then 1.6 g (5.2 mmol) of ZnN 6 ePy was added into the reaction mixture. 7 WO 01/28498 PCT/USOO/41248 To this stirred mixture at room temperature, 2.7 mL (13.7 mmol) of diisopropyl azodicarboxylate was added dropwise, causing a slightly exothermal reaction. Stirring was continued until complete consumption (TLC monitoring) of alcohol (<2hours) was observed. The heterogeneous mixture was filtered over a celite 5 pad, concentrated in vacuo and purified by column chromatography on silica gel with petroleum ether/dichloromethane (5:1) to give 2.0 g (92%) of arachidonyl azide as a colorless oil. Arachidonyl amine. To a magnetically stirred solution of 2.0 g (6.3 mmol) 10 of arachidonyl azide in 40 mL of dry diethyl ether was added 10 mL of a 1.0 M solution of lithium aluminum hydride (10 mmol) in THF dropwise at room temperature. The reaction mixture was refluxed for 3hours (h) and then quenched with wet diethyl ether. The white suspension was filtered, and the filtrate was evaporated to dryness. Chromatography on silica gel (10-50% 15 MeOH in dichloromethane) gave 1.8 g (98%) as a colorless oil. General procedure for the preparation of retro-anandamides. To a magnetically stirred solution of 0.55 mmol arachidonyl amine and 0.1 mL (0.72 mmol) of triethylamine in 4 mL of anhydrous dichloromethane was added 0.84 20 mmol of acid chloride in 1 mL dichloromethane. After stirring at room temperature for 3 h, the reaction mixture was added with brine and extracted with dichloromethane. The combined extracts were washed with brine, dried over anhydrous sodium sulfate, filtered, and evaporated. Column chromatography on silica gel with ethyl acetate/petroleum ether gave retro 25 anandamides as oil. A person of ordinary skill in the art, understanding the disclosures for the general preparation and specific preparation examples would know how to modify the disclosed procedures to achieve the above listed analogs. The materials were tested for CB2 receptor binding affinity and for CB1 30 receptor affinity (to determine selectivity for the CB2 receptor). As used herein, "binding affinity" is represented by the IC 50 value which is the concentration of 8 WO 01/28498 PCT/USOO/41248 an analog required to occupy 50% of the total number (Bmax) of the receptors. The lower the IC 50 value the higher the binding affinity. As used herein an analog is said to have "binding selectivity" if it has higher binding affinity for one receptor compared to the other receptor; e.g. a cannabinoid analog which has an 5 IC 50 of 0.1 nM for CB1 and 10 nM for CB2, is 100 times more selective for the CB1 receptor. The binding affinities (K) are expressed in nanomoles (nM) and are listed in TABLE 1. It is known that the enzymatic action of anandamide amidase can be moderated or prevented in vitro by the inclusion of phenylmethanesulfonyl 10 fluoride (PMSF). PMSF functions as a non-selective protease inhibitor. Thus the ligand binding determinations for the CB1 receptor were carried out twice, once in the presence and once in the absence of PMSF, to obtain both CB1 receptor binding affinity and a relative measure of the analog's metabolic stability. The binding affinities (K) are expressed in nanomoles (nM). 15 For the CB1 receptor binding studies, membranes were prepared from rat forebrain membranes according to the procedure of P.R. Dodd et al, A Rapid Method for Preparing Synaptosomes: Comparison with Alternative Procedures, Brain Res., 107 - 118 (1981). The binding of the novel analogues to the CB1 cannabinoid receptor was assessed as described in W.A. Devane et al, 20 Determination and Characterization of a Cannabinoid Receptor in a Rat Brain, Mol. Pharmacol., 34, 605 - 613 (1988) and A. Charalambous et al, 5'-azido A' -- THC: A Novel Photoaffinity Label for the Cannabinoid Receptor, J. Med. Chem., 35, 3076 - 3079 (1992) with the following changes. The above articles are incorporated by reference herein. 25 Membranes, previously frozen at -80*C, were thawed on ice. To the stirred suspension was added three volumes of TME (25mM Tris-HCI buffer, 5 mM MgCl 2 and 1 mM EDTA) at a pH 7.4 containing 150 /yM PMSF (made fresh in 2-propanol as a 100 mM stock). The suspension was incubated at 4*C, and after 15 min a second addition of PMSF stock brought the concentration to 300 30 yM PMSF; then the mixture was incubated for another 15 min. At the end of 9 WO 01/28498 PCT/USOO/41248 the second 15-min incubation, the membranes were pelleted and washed three times with TME to remove unreacted PMSF. The treated membranes were subsequently used in the binding assay described below. Approximately 30 pzg of PMSF-treated membranes were 5 incubated in silanized 96-well microtiter plate with TME containing 0.1% essentially fatty acid-free bovine serum albumin (BSA), 0.8 nM [ 3 H] CP-55,940, and various concentrations of anandamide analogues at 30 'C for 1 hour. The samples were filtered using Packard Filtermate 196 and Whatman GF/C filterplates and washed with wash buffer (TME containing 0.5% BSA). 10 Radioactivity was detected using MicroScint 20 scintillation cocktail added directly to the dried filterplates, and the filterplates were counted using a Packard Instruments Top-Count. Nonspecific binding was assessed using 100 nM CP 55,940. Data collected from three independent experiments performed with duplicate determinations was normalized between 100% and 0% specific binding 15 for [ 3 H] CP-55,940, determined using buffer and 100 nM CP-55,940. The normalized data was analyzed using a 4-parameter nonlinear logistic equation to yield IC 50 values. Data from at least two independent experiments performed in duplicate was used to calculate IC 50 values which were converted to K, values using the using the assumptions of Cheng et al, Relationship Between the 20 Inhibition Constant (K) and the concentration of Inhibitor which causes 50% Inhibition (IC..) of an Enzymatic Reaction, Biochem. Pharmacol., 22, 3099-3102, (1973), which is incorporated by reference herein. The CB1 ligand binding determinations in the absence of PMSF were performed in a similar manner to the above test, except without the use of 25 PMSF. For the CB2 receptor binding studies, membranes were prepared from frozen mouse spleen essentially according to the procedure of P.R. Dodd et al, A Rapid Method for Preparing Synaptosomes: Comparison with Alternative Procedures, Brain Res., 226, 107 - 118 (1 981). Silanized centrifuge tubes were 30 used throughout to minimize receptor loss due to adsorption. The CB2 binding assay was conducted in the same manner as for the CB1 binding assay except 10 WO 01/28498 PCT/USOO/41248 the assays were conducted without PMSF. Since the CB2 receptor preparation has been shown to be devoid of anandamide amidase, the presence or absence of PMSF was not considered to be determinative. The binding affinities (K,) are expressed in nanomoles (nM). 5 The following examples are given for purposes of illustration only in order that the present invention may be more fully understood. These examples are not intended to limit in any way the practice of the invention. As used herein, AA refers to that portion of the anandamide molecule having the structure: 10 Examples of the following specific analogs were prepared and tested according to the procedures and protocols discussed above. 15 11 WO 01/28498 PCT/USOO/41248 TABLE 1 0 1 AA N N 0 N-(4-Morpholinecarbonyl) arachidonylamine 5 H \ 2 AA N Br N-(3-Bromopropionyl) arachidonylamine H 0 10 3 AA N) - N-(2-Chloroacetyl) arachidonylaine H 0 N AA K OMe N-(2-Methoxyacetyl) arachidonylamine H 15 5 N-Acryloyl arachidonylaine H 6 0 AA N )O---,Arachidonylcarbamic acid ethyl ester H 20 0 7 AA ' YclN-(2-Dichhloroacetyl) arachidonylamnine H 7 cl 25 8 AA F N-(2-Difluoroacetyl) arachidonylamine H F 0 9 AA N N N-Dimethylcarbamyl arachidonylamine H 300 0 10 N N-Acetyl arachidonylaine H 11 AA NN-(4-Fluorobenzoyl) arachidonylamine 35 AA N F 12 WO 01/28498 PCT/USO/41248 TABLE 2 analog K, (CB1) nM K, (CB2) nM with PMSF without PMSF 1 23.9 35.4 100.3 2 17.4 70.6 very high 3 3.33 4.39 91.4 4 2.08 4.22 89.8 5 9.06 47.8 330 6 162.2 249.1 653.9 7 0.01 0.001 21.2 8 0.06 0.11 304.8 9 4.09 1.18 178.3 10 1.56 1.71 5320 11 180.7 174 386 Experimental preclinical data using a discriminating behavior test shows at least one of the analogs is 20 to 50 times more potent than the endogenous 5 cannabinoid ligand, anandamide. The physiological and therapeutic advantages of the inventive materials can be seen with additional reference to the following references, the disclosures of which are hereby incorporated by reference. Arnone M., Maruani J., Chaperon P, et al, Selective inhibition of sucrose and ethanol intake by 10 SR141716, an antagonist of central cannabinoid (CB1) receptors, Psychopharmacal, (1997) 132, 104-106. Colombo G, Agabio R, Diaz G. et al: Appetite suppression and weight loss after the cannabinoid antagonist SR141716. Life Sci. (1998) 63-PL13-PL1 17. Simiand J, Keane M, Keane PE, Soubrie P: SR 141716, A CB1 cannabinoid receptor antagonist, selectively 15 reduces sweet food intake in marmoset. Behav. Pharmacol (1998) 9:179-181. Brotchie JM: Adiuncts to dopamine replacement a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov. Disord. (1 998) 13 WO 01/28498 PCT/USOO/41248 13:871-876. Terranova J-P, Storme J-J Lafon N et al: Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psycho-pharmacol (1996) 126:165-172. Hampson AL Grimaldi M. Axpirod J. Wink D: Cannabidiol and (-) n 9 tetrahydrocannabinol are neuroprotective 5 antioxidants. Proc. Nati Acad Sci. USA (1998) 9S:8268-8273. Buckley NE, McCoy KI, Mpzey E et al Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB, 2 receptor. Eur. J Pharmacol (2000) 396:141 149. Morgan Dr: Therapeutic Uses of Cannabis. Harwood Academic Publishers, Amsterdam. (1997). Joy JE, Wagtson SJ, Benson JA: Mariiuana and Medicine 10 Assessing the Science Base. National Academy Press, Washington, DC, USA (1999). Shen M. Thayer SA: Cannabinoid receptor agonists Orotect cultured rat higpocampal neurons from excitotoxicity. Mol. Pharmacol (1996) 54:459-462. DePetrocellis L, Melck D, Palmisano A. et al: The endogenous cannabinoid anandamide inhibits human breaast cancer cell proliferation. Proc NatI. Acad. Sci 15 USA (1998) 95:8375-8380. Green K. Marijuana smoking vs. cannabinoids for glaucoma therapy. Arch. Ophibalmol. (1998) feb 433-1437. Hemming M, Yellowlees PM, Effective treatment of Tourette's syndrome with marijuana. J. Psychopharmacol, (1993) 7:389-391. Muller-Vahl KB, Schneider U, Kolbe H, Emrich, HM. Treatment of Tourette's syndrome with delta-9 20 tetrahydrocannabinol. Am. J. Psychiat. (1999) 156-195. Muller-Vahl KB, Kolbe H, Schneider U, Emrich, HM Cannabis in movement disorders. Porsch. Kompicmentarmed (1999) 6 (suppl. 3) 23-27. Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The perceived effects of smoked cannabis on patents with multiple sclerosis, Eur. Neurol. (1997) 38-44-48. Pinnegan-Ling D, Musty R. 25 Marinol and phantom limb pain: a case study. Proc Inv. Cannabinoid Rea. Sec. (1994):53. Brenneisen R, Pgli A, Elsohly MA, Henn V. Spiess Y: The effect of orally and rectally administered L 9 - tetrahydrocannabinol on spasticity, a pilot study with 2 patients. Int. J. Clin Pharmacol Ther. (1996) 34:446-452. Martyn CN. Illis LS, Thom J. Nabilone in the treatment of multiple sclerosis. Lancet 30 (1995) 345:579. Maurer M, Henn V, Dittrich A, Hofmann A. Delta-9 tetrahydrocannabinol shows antispastic and analgesic effects in a single case 14 WO 01/28498 PCT/USOO/41248 double-blind trial. Eur. Arch. Psychiat. Clin. Neurosci. (1990), Z40:1-4. Herzberg U, Eliav E, Bennett GJ, Kopin IJ: The analgesic effects of R(+) WIN 55,212-2 mesylate, a high affinity cannabinoid agonist in a rare model of neuropathic pain. Neurosci. Letts. (1997) 221:157-160. Richardson JD, Kilo S. Hargreaves KM, 5 Cannabinoids reduce dryperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain (1998) 75:111-119. Ricardson JD, Aanonsen I, Hargreaves KM: Antihyperalgesic effects of a spinal cannabinoids. Eur. J. Pharmacol. (1998) 346:145-153. Calignano A, La Rana G. Diuffrida A, Piomelli D: Control of pain initiation by endogenous cannabinoids. Nature (1998) 10 394:277-291. Wagner JA, Varga K, Jarai Z, Kunos G: Mesenteric vasodialtion mediated by endothelia anandamide receptors. Hypertension (1999) 33:429 434. Schuel, H., Burkman, L.J., Picone, R.P., Bo, T., Makriyannis, A., Cannabinoid receptors in human sperm. Mol. Biol. Cell., (1997) (8), 325a. The inventive analogs described herein, and physiologically acceptable 15 salts thereof, have high potential when administered in therapeutically effective amounts for providing a physiological effect useful to treat pain; peripheral pain; glaucoma; epilepsy; nausea such as associated with cancer chemotherapy; AIDS Wasting Syndrome; cancer; neurodegenerative diseases including Multiple Sclerosis, Parkinson's Disease, Huntington's Chorea and Alzheimer's Disease; to 20 enhance apetite; to reduce fertility; to prevent or reduce diseases associated with motor function such as Tourette's syndrome; to provide neuroprotection; to produce peripheral vasodilation and to suppress memory. Thus, another aspect of the invention is the administration of a therapeutically effective amount of an inventive compound, or a physiologically acceptable salt thereof, to an individual 25 or animal to provide a physiological effect. Those skilled in the art will recognize, or be able to ascertain with no more than routine experimentation, many equivalents to the specific embodiments of the invention disclosed herein. Such equivalents are intended to be encompassed by the scope of the invention. 15

Claims (3)

1. A compound of the formula R2 Y-R, -- - R 3 wherein: X is selected from the group consisting of C=0, and C= S; Y is NH; R, is selected from the group consisting of n-C 5 HOZ, n-C 6 H 12 Z, n-C 7 H 14 Z, and 1'1'-C(CH 3 ) 2 (CH 2 ) 5 CH 2 Z, wherein Z is selected from the group consisting of H, halogen, N 3 , NCS, OH, CN and -CH = CH-I; R 2 is selected from the group consisting of H, CH., and (CH 3 ) 2 ; and R 3 is selected from the group consisting of CH 3 , CHX 2 , CH 2 X, CH = CH 2 , CH 2 0CH 3 , -C=CH, -O(CH 2 )nCH 3 , -S(CH 2 )nCH 3 , -N--(CH2)nCH (CH2)mCH3 wherein n and m are each a number from 0 to about 7, wherein X is selected from the group consisting of -X y N and CH and Y and Z are each selected from the z group consisting of (CH 2 )n, 0, N, and S, and wherein n is a number from 0 to about 7, X-- \ wherein X, Y and Z are each selected from the Y z/ group consisting of CH and N, wherein R4, R5 and R6 are each selected from he group consisting of halogen, N 3 , NCS, OCH 3 , CH 3 , R4 CH 2 CH., NO 2 , NH 2 and phenyl. 16 WO 01/28498 PCT/USOO/41248

2. The compound of claim 1 wherein X is C=0.

3. A method of preferentially stimulating the CB1 receptors in an individual or animal comprising administering to the individual or animal a therapeutically effective amount of a compound having the formula: R2 -R Y R 3 wherein: X is selected from the group consisting of C=0, and C= S; Y is NH; R 1 is selected from the group consisting of n-C 5 H 10 Z, n-C6 12 Z, n-C 7 H 14 Z, and 1'1'-C(CH 3 ) 2 (CH 2 )sCH 2 Z, wherein Z is selected from the group consisting of H, halogen, N3, NCS, OH, CN and -CH = CH-l; . R 2 is selected from the group consisting of H, CH 3 , and (CH 3 ) 2 ; and R 3 is selected from the group consisting of CH 3 , CHX 2 , CH 2 X, CH=CH 2 , CH 2 0CH 3 , -C=CH, -O(CH 2 )nCH 3 , -S(CH 2 )nCH 3 , -N-(CH2)nCH (CH 2 )mCH 3 wherein n and m are each a number from 0 to about 7, wherein X is selected from the group consisting of -- , y N and CH and Y and Z are each selected from the z group consisting of (CH 2 )n, 0, N, and S, and wherein n is a number from 0 to about 7, 17 WO 01/28498 PCT/USOO/41248 X- wherein X, Y and Z are each selected from the group consisting of CH and N, wherein R4, R5 and R6 are each selected from he group consisting of halogen, N 3 , NCS, OCH 3 , CH 3 , R4 CH2CH3, NO2, NH 2 and phenyl. 18